Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Neurothera LabsTSXV:NTLX +12.07%31 Receivables Turnover is 0.00 as of Dec. 2025. GuruFocus rates TSXV:NTLX with a GF Score™ of 31/100. The stock has 2 warning signs investors should review. Among 948 Drug Manufacturers companies, Neurothera Labs ranks worse than 105485.13% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Neurothera Labs's Revenue for the
three
months ended in Dec. 2025 was C$0.00 Mil. Neurothera Labs's average Accounts Receivable for the
three
months ended in Dec. 2025 was C$0.01 Mil.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Neurothera Labs Receivables Turnover Related Terms
Neurothera Labs Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Neurothera Labs's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSXV:NTLX vs LLY, JNJ, ABBV: Receivables Turnover Comparison
For the Drug Manufacturers - General subindustry, Neurothera Labs's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neurothera Labs Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Neurothera Labs's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Neurothera Labs's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neurothera Labs (TSXV:NTLX) has a Receivables Turnover of 0.00 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Neurothera Labs and its competitors. According to the industry distribution chart, Neurothera Labs ranks #999999 out of 948 companies in the Drug Manufacturers industry.
Is Neurothera Labs' Receivables Turnover too high?
Neurothera Labs' current Receivables Turnover is 0.00. Based on the distribution chart, Neurothera Labs ranks #999999 out of 948 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Neurothera Labs has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Neurothera Labs' Receivables Turnover compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Neurothera Labs ranks #999999 out of 948 companies for Receivables Turnover. This places Neurothera Labs in the lower half of its industry. The industry median Receivables Turnover is 5.07. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 948 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Neurothera Labs and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neurothera Labs's current Receivables Turnover is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurothera Labs stock overvalued right now?
Neurothera Labs (TSXV:NTLX) has a current Receivables Turnover of 0.00. The current Receivables Turnover is 0.00. Neurothera Labs' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Neurothera Labs (TSXV:NTLX), the current Receivables Turnover is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Address325 Front Street West, 2nd Floor, Toronto, ON, CAN, M5V2Y1
Neurothera Labs Inc is a specialty clinical-stage pharmaceutical company. The company's focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid therapies. With this focus, it has been engaged in developing and testing pharmaceutical compositions comprised of N-acylethanolamines, CBD and/or other cannabinoid receptors agonists. The Company is currently engaged in development programs based on tetrahydrocannabinol and/or non-psychoactive cannabidiol for the treatment of Tourette syndrome, Alzheimer's disease and agitation, autism spectrum disorder and Status Epilepticus.
31GF Score
Get the complete analysis for TSXV:NTLX
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:NTLX has been successfully added to your 
